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In Europe and the USA, at least one person in four is exposed every day to inhalant allergens
of mammalian origin, a considerable number is regularly exposed for professional reasons
and almost everyone is occasionally exposed to inhalant allergens from pets or domestic
animals. The production of IgE to these inhalant allergens, often complicated by asthma
and rhinitis, defines the atopic status. However, the immune response to these allergens
largely imprints the cellular immune compartment and also drives non-IgE humoral immune
responses in the allergic and non-allergic population. During the recent years, it has become
clear that IgE antibodies recognize mammalian allergens that belong to three protein or
glycoprotein families: the secretoglobins, the lipocalins, and the serum albumins. In this
article, we review the humoral and cellular immune responses to the major members of
these families and try to define common characteristics and also distinctive features.
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INTRODUCTION
The immune system of the respiratory tract of children and adults
is continuously being exposed to inhaled particles of inorganic
and organic origin. Some particles or molecules have potential
adjuvant activities, some have allergenic potential such as mite
allergens, other molecules for instance of human origin are devoid
of immunogenic or allergenic properties. In their daily environ-
ment, most people are also exposed to allergens of mammalian
origin. The exposure rate can be high for people having pets at
home, for farmers who keep or raise domestic animals, and for
persons who have other types of professional contact with ani-
mals, for instance veterinarians or animal workers in a laboratory
setting. However, even people that do not have direct contact with
animals may have contact with inhalant allergens that have been
shed by animals or that have been carried to public places by ani-
mal owners, as documented by the presence of cat allergens in
schools and other public places (1). Indeed, allergic sensitization
to animal allergens is common in persons who do not have pet ani-
mals at home. Data from a large pan-European study show that
about 27% of the patients referred to an allergy center for allergic
reactions to inhalant allergens were sensitized to cat and/or dog
(2). Sensitization was particularly high in Nordic countries, the
highest sensitization rate for dogs reaching 56% in Denmark.
As dendritic cells combine antigen presentation capacities with
sensing of signals of innate immunity, they are the master players
in all types of adaptive immunity. The important role of airway
epithelial cells in alarming dendritic cells for allergic sensitization
has more recently been highlighted (3, 4). In contrast to certain
other inhalant allergens (Der p 1, Der p 2), an inherent capacity of
mammalian allergens to trigger the pathways of innate immunity
has not been convincingly shown, although a recent publication
argues for an enhancing activity of some mammalian allergens
on toll-like receptor (TLR) activation by lipid ligands (5). Aller-
gens of mammalian origin do not only induce IgE antibodies but
also IgG isotypes and different T cell responses (Th2, Th1, Th17,
and regulatory T cells) in allergic and non-allergic persons. We
will review the immune responses to three major mammalian
allergen families: secretoglobins, lipocalins, and serum albumins.
We will focus on the most prominent of their members and
try to distinguish common and specific characteristics based on
published data.
SECRETOGLOBINS
Fel d 1, the major cat allergen, is a 35-kDa tetrameric glycoprotein
formed of two non-covalently linked heterodimers (6,7). Each het-
erodimer comprises a light alpha-chain (or chain 1) and a heavy
beta-chain (or chain 2) containing an N -linked oligosaccharide
(8). Until the recent description of rabbit lipophilin Ory c 3 (9),
Fel d 1 was the only known allergen of the secretoglobin fam-
ily. Both molecules display little sequence identity (24%) despite
a high structural identity. There are no protein stretches of more
than three consecutive identical amino acids which are common to
the two molecules and which could form identical linear epitopes.
Surface representation of Fel d 1 overlaid with the sequence of Ory
c 3 does not show evidence for significant common discontinuous
epitopes (Figure 1). Indeed, IgE cross-reactivity between Fel d 1
and Ory c 3 could not be shown (9).
EXPOSURE AND EFFECT ON THE HUMORAL IMMUNE RESPONSE
Cats are present in 24% of European Union and up to 37% of
United States households (11). The level of airborne Fel d 1 in
homes with a cat was found to be in the range of 1.8–578 ng/m3, a
comparable level of airborne Fel d 1 ranging from 2.8 to 88.5 ng/m3
was also measured in 25% of homes without a cat (12). The quan-
tity of Fel d 1 inhaled on airborne particles by children in homes
with a cat has been estimated to be 1µg/day, which is about 100
times the quantity of mite or pollen allergens inhaled in 1 day
(13, 14). At the age of 4, already 5.8% of children of a U.K. birth
cohort study were sensitized to cat (15) while 16.9% of adults
were sensitized in another study (16). In a recent study including
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FIGURE 1 | Comparison of Fel d 1 and Ory c 3 composing the
secretoglobin group. Surface representation of Fel d 1 (2EJN) (7) colored by
sequence conservation with Ory c 3 (Q9GK63; Q9GK67) (9). Sequence
conservation was determined through Consurf (10), the highly variable
sequence conservation was identified as deep blue, the average was in
white, and the conserved sequences are denoted in deep red.
96 cat-allergic patients, IgE antibodies to Fel d 1 represent on aver-
age 55% of a cat-specific IgE response, however, with a range from
0 to 100%. Fel d 1 was the cat allergen that bound the highest
amount of IgE in 65% of the patients (17). Surprisingly, children
exposed to cat during the first year of life are less often skin prick
test positive to cat at 12–13 years than controls (18). Exposure to
high concentrations of Fel d 1 was found to be associated with
lower sensitization in terms of specific IgE but increased levels of
IgG (and IgG4) antibodies to Fel d 1 which has led to the con-
cept of “modified Th2 response” (19). Exposure to cat and Fel d 1
was associated with three patterns of humoral responses: an aller-
gic response characterized by the presence of IgE and IgG (often
IgG4) to Fel d 1, a modified Th2 response characterized by pres-
ence of IgG (mostly IgG4) antibodies but absence of IgE response
to Fel d 1, and thirdly an absence of humoral response to Fel d
1 characterized by failure to produce specific IgE or IgG to Fel d
1, even though exposure to Fel d 1 took place (20). However, the
analysis of IgE, IgG, and IgG4 antibodies to Fel d 1 in relation to
wheezing in two large birth cohorts showed that allergen-specific
IgG but not IgG4 antibody levels were related to improved wheez-
ing in children with Fel d 1-specific IgE (21). At this point, it
might be interesting to note that a phase I/II a clinical trial using
intralymphatic immunotherapy with a technology called modu-
lar antigen translocation (MAT) linking Fel d 1 to a construct
enhancing its presentation by the MHC class II pathway, increased
Fel d 1-specific IgG4 production (22). Thus, exposure to high
concentrations of Fel d 1 in the daily environment is associated
with clinical improvement in parallel to increased levels of Fel d
1-specific IgG and in particular IgG4 antibodies (19). A similar
modified Th2 response can be achieved by high Fel d 1 loading of
the antigen-presenting pathway by intralymphatic immunother-
apy and MAT technology (22). This is in line with the concept that
a modified Th2 response is associated with high antigen exposure.
T CELL RESPONSE AS MEASURED EX VIVO
The frequency of Fel d 1-peptide-specific T cells in peripheral
blood as assessed by tetramer technology using a chain 1 peptide
(aa 32–48) – DRB1*01:01 tetramer complex in a population of
HLA – DRB1*01:01 positive cat-sensitized patients with atopic
dermatitis and controls gave the following results. Atopic der-
matitis patients had 3–53:100.000 and controls about 3:100.000
tetramer-positive CD4 T cells in their peripheral blood (ex vivo).
The majority of about 80% expressed a central memory phenotype
(with high surface expression of CCR7, CD62L, CD27, and CD28)
(23). Comparable results were obtained for Fel d 1-specific CD4
cells with tetramers containing six different peptides bound to
six different HLA class II molecules (24). Peptide-specific CD4
cells ranged from 1:7000 to 1:300000 in allergic subjects. In sub-
jects without allergy, tetramer-positive CD4 T cells were barely
detectable. Nearly all cells exhibited a central memory pheno-
type, however, CCR7 expression was heterogeneous. A relevant
percentage of cells were CCR4+, interpreted as a commitment to
migrate to non-lymphoid sites. In comparison, in birch-allergic
persons, the percentage of CD4 T cells recognizing MHC class
II tetramers containing an immunodominant peptide was about
500:100.000 in allergic and 300:100.000 in non-allergic persons
during the peak pollen season (25). This is more than one order
of magnitude higher than for Fel d 1 in cat-allergic persons. In
birch-allergic persons, the cells were mainly of an effector mem-
ory phenotype (IL-5 and some IL-10). The cells of non-allergic
persons were of central memory phenotype (secreting IFN-γ and
IL-10) in response to the allergen. Peptide-positive cells could not
be detected directly ex vivo outside the pollen season. Their num-
ber was estimated to be at that time point 2–3 logs lower than
during the peak pollen season (25). One possible explanation for
this difference in peptide-specific T cells could be a smaller initial
peripheral T cell repertoire against Fel d 1 due to a stronger thymic
deletion of T cells recognizing epitopes of mammalian origin (phy-
logenetically closer to human epitopes) than T cell recognizing
epitopes on molecules of plant origin. It is, however, more likely
that the greater number of CD4 T cells recognizing MHC class II
tetramers loaded with immunodominant pollen-derived peptides
is due to the seasonal boosting of cellular immune response linked
to pollen exposure.
PEPTIDES AND PEPTIDE IMMUNOTHERAPY
By T cell epitope mapping with peptides, amino acid positions
1–10 and 16–24 of Fel d 1 chain 2 were found to be associated
with a HLA-DR7-restricted secretion of high IL-10, respectively
IFN-γ in PBMC cultures of persons with a modified Th2 response
(20). Previous work had defined Fel d 1 T cell epitopes mainly
on chain 1, by means of cell proliferation assays of T cell lines
established from persons allergic to cats (26). Intradermal admin-
istration of short overlapping peptides derived from chain 1 of
Fel d 1 that did not cross-link IgE, did not elicit a visible early
or late cutaneous response, but caused late asthmatic reactions
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in 9/40 cat-allergic asthmatics (27). The individual peptides were
able to induce proliferation and IL-5 secretion in a HLA class II
restricted manner from T cell lines established from asthmatic
subjects, indicating IgE-independent, T cell-dependent allergic
reaction. Determination of the binding affinities of Fel d 1 pep-
tides to 10 commonly expressed HLA-DR molecules, combined
with their proliferative and cytokine responses (IFN-γ, IL-10, and
IL-13) in cat-allergic persons allowed a comprehensive identifi-
cation of immune-dominant sequences including those on chain
2 (28). A short peptide immunotherapy course with a combi-
nation of promiscuous peptides (serving as restriction element
to different HLA-DR molecules) improved the ocular and nasal
components of rhino-conjunctivitis symptoms in subjects with
cat allergy, with a treatment effect persisting 1 year after the start
of treatment (29). This approach uses only short peptides (12–16
amino acids long) which are not recognized by IgE antibodies able
to trigger an early asthmatic response through mediator release by
basophils and mast cells. These short peptides are also not likely
to be recognized by surface-bound IgM and thus interfere at the
immature B cell level. Their effect is rather due to a dampening
of the effector T cells for instance IL-5-secreting T cells impli-
cated in the late allergic asthmatic response. The impact could
be due to changes of the helper or regulatory cellular functions.
Of course, an immune system modified by this approach at the
cellular level could secondarily be susceptible to changes at the
humoral level after later inhalation of Fel d 1 molecules present in
the environment.
LIPOCALINS
Lipocalins represent the largest group of mammalian inhalant
allergens. They are major allergens from dog, horse, cattle, guinea
pig, rat, mouse, rabbit, and hamster (30). Lipocalins have a com-
mon tertiary structure composed of a central β-barrel formed of
eight anti-parallel β-strands (31). Lipocalins were shown to carry
small hydrophobic molecules such as retinol, steroids, odorants,
and pheromones in their internal binding pocket. Despite a highly
conserved structural similarity, lipocalins generally have a very
low amino acid identity, which for some of them can be lower
than 20% (32), a fact that makes IgE cross-reactivity among these
lipocalins unlikely. Until recently, it was assumed that IgE cross-
reactivity between lipocalins would be limited to isolated epitopes
with great amino acid identity between lipocalins (33). However,
besides lipocalins with very low amino acid identity, a group with
greater homologies and IgE cross-reactivity has been individu-
alized. It comprises the following allergens: Fel d 4 (cat), Can f 6
(dog), Equ c 1 (horse), Ory c 4 (rabbit), Mus m 1 (mouse), and Rat
n 1 (rat) (Table 1). Pairwise sequence comparisons show identities
in the range of 47–67% whereas other cat and dog lipocalins have
only weak identities. There is also another lipocalin pair namely
Fel d 7 and Can f 1 that shares 63% identity at the amino acid level
and which might give rise to cross-sensitization. Concerning the
main group, IgE cross-reactivity was first shown between mouse
and rat urinary lipocalins using sIgE inhibition (34). Indeed at the
amino acid level, there exists an identity of 64% between the major
rat lipocalin Rat n 1 and mouse lipocalin Mus m 1. More recently
considerable IgE cross-reactivity was shown between dog lipocalin
Can f 6 and cat Fel d 4 (amino acid identity 67%) and between
Table 1 | Amino acid identities (%) and IgE cross-reactivity between
members of a mammalian lipocalin subgroup.
Fel d 4 67 (35, 37)a 67 (37)a 63 49 55
Can f 6 67 (35, 37)a 57 (37)a 58 47 52
Equ c 1 67 (37)a 57 (36)b (37)a 52 46 (33)a 47
Ory c 4 63 58 52 51 54
Mus m 1 49 47 46 51 64 (34)a
Rat n 1 55 52 47 54 64 (34)a
Fel d 4 Can f 6 Equ c 1 Ory c 4 Mus m 1 Rat n 1
Amino acid identities between lipocalins are given as %.
aDocumented IgE cross-reactivity (allergen-specific inhibition).
bDocumented IgE cross-reactivity with clinical history of cross-reactivity.
Literature references are given in brackets.
Vertical: sensitizing allergen. Horizontal: cross-reactive allergen.
these lipocalins and horse lipocalin Equ c 1 (35–37). IgE cross-
reactivity between Equ c 1 and Can f 6 was shown to be clinically
relevant in a horse- and dog-allergic patient who showed no spe-
cific IgE to known dog allergens except Can f 6 (36). IgE reactivity
of this patient to Can f 6 could be completely inhibited by Equ c 1.
Can f 6 and Equ c 1 share 57% amino acid identity. Table 1 gives
a summary of amino acid identity and cross-reactivity between
members of the cross-reactive lipocalin group. Structural identity
between Equ c 1, Fel d 4, and Can f 6 are visualized in Figure 2,
structural identities between Mus m 1, Rat n 1, and Ory c 4 are
shown in Figure 3.
EXPOSURE AND EFFECT ON THE HUMORAL IMMUNE RESPONSE
Lipocalins are shed into the environment by animal dander and
secretions. Dog allergen Can f 1 is ubiquitously present in human
residential environment. The most probable mechanism of aller-
gen transfer to public places is clothing (1). Lipocalins are found
both in airborne and settled dust. Although Fel d 1 and Can f
1 belong to different protein families, a number of studies have
shown that allergen levels found in airborne or settled dust are in
the same range of magnitude for both molecules (38).
The importance of mouse allergens was initially demonstrated
in the occupational setting (39). However, the role of mouse aller-
gen exposure in domestic environments has also gained attention.
Mus m 1, the major mouse allergen, is prevalent in US urban
and suburban residential environments. It has been shown to
be related to asthma morbidity (40–42). Importantly, airborne
and settled dust mouse allergen levels were shown to vary over
time in a given home, implying that environmental conditions
of sensitized patients may change from high to low exposure
and vice versa. Conditions of high exposure reached values up
to 5.68 ng/m3, which are comparable to measurements obtained
in animal facilities.
The effect of allergen concentration on the immune response
has been addressed in a prospective study analyzing the immune
response of newly hired employes of a mouse facility over time.
The concentrations of Mus m 1 in the air ranged from 0.09 to
9.88 ng/m3, the median of the allergen concentrations over time
being 0.69 ng/m3. By 24 months, 23% of the participants had
developed a positive SPT. Interestingly, the risk of becoming pos-
itive was not linear, increasing from low to moderate levels of
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FIGURE 2 | Comparison of the cross-reactive lipocalin group from horse (Equ c 1), cat (Fel d 4), and dog (Can f 6). Surface representation of Equ c 1
(1EW3) (69) colored by sequence conservation with Fel d 4 (Q5VFH6) (70), Can f 6 (H2B3G5) (35).
FIGURE 3 | Comparison of the cross-reactive lipocalin group from rat (Rat n 1), mouse (Mus m 1), and rabbit (Ory c 4). Surface representation of Rat n 1
(1MUP) (71) colored by sequence conservation with Ory c 4 (U6C8D6) (72) and Mus m 1 (P02762) (73).
exposure, peaking at approximately 1.2 ng/m3, and then decreas-
ing from moderate to high levels of exposure (43). Eight percent
had developed mouse-specific IgG4, the incidence increasing with
increasing levels of mouse allergen exposure. Ten percent of the
participants had developed mouse-specific IgG1–3 with a non-
significant association with higher exposure. A previous cross-
sectional occupational study had shown that high exposure to rats
was associated with lower rates of symptoms and specific IgE to
rat urine allergen (containing Rat n 1) but an increased frequency
of highly specific IgG and IgG4 (44).
A recent study addressing specific IgE, IgG1, IgG4 levels and the
peripheral blood mononuclear cytokine responses to eight sepa-
rate cat allergens in cat-allergic and in cat non-allergic persons
showed IgG4 antibodies to Fel d 4 in 12% of allergic persons and
in only 3% of non-allergic persons (17). Although IgG1 antibodies
to Fel d 1 were found in allergic and non-allergic persons, there
were none detected against Fel d 4. Another recent study analyzing
on a microarray system of IgE and IgG antibodies to a series of
dog, cat, and horse allergens showed that almost all the patients
but also controls had IgG antibodies to the cross-reacting lipocalin
group (Fel d 4, Can f 6, and Equ c 1) (45).
T CELL RESPONSES TO LIPOCALIN ALLERGENS
Rat n 1 allergen purified from rat urine and pools of overlap-
ping peptides spanning Rat n 1 were tested for the proliferative
responses of PBMCs of rat-allergic individuals, rat-exposed but
non-allergic individuals and non-exposed, non-allergic individu-
als (46). The proliferative responses to Rat n 1 of the three groups
were similar and weak with a median stimulation index below
2 (but with an extremely great range between 0.01 and 22.2).
Nevertheless, four peptide pools induced with high frequency
weak positive responses in allergic individuals in comparison to
non-allergic referents (46). Interestingly, the levels of IL-5 were sig-
nificantly increased in supernatants of PBMCs stimulated with rat
urinary protein from allergic subjects, compared to non-allergic
control subjects and even more so when compared to non-exposed
controls when stimulated with rat urinary protein. Four simi-
lar epitope areas had previously been defined in the cow dander
allergen Bos d 2 in cow-asthmatic individuals (47). Here also, the
proliferative response of PBMCs to native Bos d 2 had been weak
and the four epitopes concentrated on the conserved regions of
the molecule had been most clearly defined by the proliferative
response of a number of T cell clones established from five cow-
allergic patients. According to their cytokine-producing pattern,
37% of the clones were classified as Th0-like (IL-5, IL-4, IFN-γ),
7.9% were Th1-like (IFN-γ), and 55% were Th2-like (IL-4, IL-5).
Using HLA class II-peptide tetramer technology, naïve Bos d 2-
specific T cells of PBMC cultures of individuals with or without
allergy were of similar frequency, whereas the frequency of CD4+,
CD45RO+ memory cells appeared to be higher in subjects with
allergy (48). These findings were confirmed by a recent study on
the CD4 T cell response to Equ c 1, the major horse lipocalin
allergen (49). Allergic and non-allergic subjects had a similar low
frequency of Equ c 1-specific CD4 T cells, but the cells from the
allergic subjects had a stronger proliferative response, were pre-
dominantly Th2 biased and originated mostly from memory CD4
T cells.
T cell epitopes have also been mapped for the major allergens
of dog and horse, Can f 1 and Equ c 1, respectively (50, 51). Seven
epitope regions were defined for Can f 1 and on average, patients
recognized three epitopes. T cell lines from allergic patients pro-
duced more IL-4 than those from healthy controls. However,
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depending on the peptide used, they produced also more IL-10
or more IFN-γ (52). A comparison of Can f 1-specific T cell lines
generated from dog-allergic and non-allergic but exposed persons
showed an absence of IL-4 secreting T cell lines in non-allergic
persons, while IL-5, IL-10, IFN-γ, and IL-17 lines were found in
both groups although at different frequencies (53). Specific T cell
lines established from 10 horse-allergic patients determined 8 epi-
tope regions and 1 dominant epitope in the C-terminal region of
Equ c 1 (51). Similarly to the findings on Rat n 1 and Bos d 2,
epitopes are clustered in a few regions and they elicit only weak
T cell responses in PBMCs which are enhanced in the T cell lines
obtained after several stimulation cycles (51).
SERUM ALBUMINS
Serum albumins represent the major protein component in the cir-
culatory system of mammals. They are produced by hepatocytes
and have a molecular weight in the range of 66–69 kDa. They con-
tribute significantly to colloid osmotic blood pressure and aid in
the transport of many endogenous and exogenous ligands. The
albumin molecule is very flexible, it has an α-helical structure
stabilized by several disulfide bridges and is divided into three
domains (54). Serum albumins are also present in body fluids and
on dander. In house dust samples, concentrations of human serum
albumin (HSA) have been measured in the range of 40–301µg/g
dust (55). Again, this is the range of the settled dust amounts mea-
sured for Fel d 1 and Can f 1, two molecules representative of a
different allergen family. There are no commercial tools available
up to date for the specific measurement of animal albumins in
dust samples.
IMMUNE RESPONSE TO SERUM ALBUMINS
The immune response to serum albumins is well-documented at
the antibody level, however, there are few data on the cellular
response to serum albumins. Specific IgE to dog serum albumin
(DSA) were first described in dog dander asthmatic children who
were prick test positive to DSA (9 out of 80) (56). The titers
of anti-DSA IgG measured did not correlate with specific IgE
titers. Lymphocyte transformation tests in anti-DSA IgE-positive
patients were weak except for one patient. In subsequent reports,
the importance of DSA as a cross-reactive allergen was established.
In a study with 110 dog-allergic patients, 35% were shown to have
IgE against DSA (57). IgE antibodies from several selected patients
bound also to albumins from other species such as cat, mouse, and
rat. Histamine release with the different albumins was shown for
one patient. A more extensive analysis of cross-reactivity was per-
formed on a sample of 200 patients allergic to animal dander (58).
Thirty percent of these patients presented IgE reactivity to albu-
mins in animal hair/dander extracts and were further tested in
dot-blot experiments for cross-reactivity with 11 different mam-
malian albumins. The majority of the patients’ IgE recognized a
large spectrum of albumins; some, however, displayed a highly
selective reactivity.
IgE CROSS-REACTIVITY BETWEEN INHALED AND INGESTED OR
SYSTEMICALLY ADMINISTERED SERUM ALBUMINS
Despite their high level of cross-reactivity, albumins were con-
sidered minor allergens without documented clinical significance.
This was challenged by a case report of a severe anaphylactic reac-
tion after artificial insemination in a patient sensitized to animal
dander (59). Bovine serum albumin (BSA), a compound of the
medium used, could be identified as trigger for the reaction. A first
report on cat-allergic patients experiencing anaphylactic reactions
upon consumption of pork meat coined the term pork–cat syn-
drome (60). Another study investigated the role of serum albumin
in this syndrome. The sensitization of cat-allergic patients to cat
serum albumin was analyzed and possible cross-sensitization pro-
files to pork albumin were determined by inhibition assays (61).
The frequency of sensitization to cat albumin ranged between 14
and 23%, depending on the cohort, while sensitization to porcine
serum albumin ranged from 3 to 10%, respectively. About 1/3
of the patients sensitized to porcine serum albumin are likely to
experience adverse reaction by the consumption of pork, especially
ham or sausages, as albumins are heat-labile proteins. Statistically,
about 1–3% of cat-allergic patients would be at risk for adverse
reactions to pork (61). The described cases all originated from
Europe, but recently several cases with immediate type allergic
reactions upon pork consumption have been reported in the US
(62). Testing for serum IgE to cat and pork serum albumin allows
discriminating this syndrome from the reactions of delayed food
allergy related to the presence of IgE directed to alpha-gal sugar
determinants on meat (63). The high level of IgE cross-reactivity
between serum albumins hampers the determination of the sen-
sitizing molecule. The clinical history of sensitization, the level of
specific anti-albumin IgE titers as well as IgE inhibition data have
to be taken into account to establish a correct diagnosis. Although
IgE cross-reactivity is most frequent between mammalian albu-
mins, cross-reactivity may also occur between cat and chicken
albumin which share only 46% identical amino acids (64). BSA is
an important allergen of meat and milk. IgG and IgA responses
to BSA and different fragments thereof have been analyzed in
three cohorts: unselected persons, new-onset insulin-dependent
diabetes mellitus patients, and atopic patients (65). IgG and IgA
antibodies to BSA were inversely correlated with age in the nor-
mal population. In all three cohorts, IgG antibodies recognized all
three BSA domains with an equivalent frequency, however, only
31–46% of the subjects’ IgA antibodies were able to bind to the N-
terminal part of the BSA molecule. This finding correlated with the
fact that the N-terminal domain was also the first to be degraded
in simulated gastric fluid experiments, suggesting that systemic
IgG antibody responses and gut-associated lymphoid tissue IgA
responses to the food allergen are independent.
Mammalian serum albumins display a very high amino acid
identity (72–82%) to HSA (66). This leaves very little space for the
discrimination of self from non-self. It is interesting to note that up
to now no clear autoimmune reaction to HSA has been proven. The
role of the so-called ABBOS peptide, an epitope present on the BSA
molecule, has been controversially discussed in the development
of insulin-dependent diabetes mellitus (67).
It has been hypothesized that, at least for food allergens, mole-
cules with a high degree of similarity to human homologs would
be poorly immunogenic (68). Above a threshold of 62% sequence
identity, proteins were found to be rarely allergenic. BSA, an
allergen of cow’s milk is an exception as it shares 75.6% iden-
tity with HSA. The respiratory allergenic albumins present even
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identities of 81.7% (cat), 79.8% (dog), and 76.1% (horse) to HSA.
The structural features of mammalian and avian serum albu-
mins have been addressed in a recent review by Chruszcz et al.
(66). Their three-dimensional structure is crucial for antibody
binding and allergenicity. Albumins are sensitive to heat treat-
ment and thoroughly cooked food is generally tolerated by allergic
patients.
CONCLUSION
Inhalant mammalian allergens are capable of eliciting a large vari-
ety of immune responses, of which production of specific IgE is
only one. At the humoral level, a particular aspect is the high
IgE cross-reactivity mainly within the serum albumins but also
a cross-reactive lipocalin group. At the T cell level, the overall
proliferative response to mammalian allergens is rather low, with
nevertheless important variations. Allergen-specific CD4 T cells
in peripheral blood of allergic persons are slightly more frequent
than in non-allergic persons and predominantly have a Th2 cen-
tral memory profile. The studies with Fel d 1 peptides have clearly
established the existence of an effector cellular immune response,
which has a pathogenic potential which is independent of the
humoral IgE response. High allergen exposure, whether natural or
immunotherapy-induced, is correlated to clinical benefit in par-
allel to the production of high titers of allergen-specific IgG4. A
causal relationship between the two observations needs still to be
proven. The issue of an autonomous immunogenicity and aller-
genicity of mammalian allergens is still elusive, the possibility of
an allergenic bystander effect of other inhaled particles with adju-
vant properties is a realistic option. At last, mammalian allergens,
especially those whose amino acid sequence is close to that of their
human homologs, are unique tools to study the immune response
at the frontier between self and non-self.
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